MedTrace Logo

Defining Recurrent Disease With Axumin™

NCT03996993 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-06-25

No results posted yet for this study

Summary

This project seeks to use advanced imaging (specifically, positron emission tomography/computed tomography \[PET/CT\]) to detect, locate, and characterize recurrent disease in the setting of patients with prostate cancer.

Conditions

Interventions

DRUG

Casodex, Axumin

Patients will receive hormone therapy if Axumin positive area appears.

RADIATION

Salvage Radiation, Axumin

Patients will receive salvage radiation therapy if Axumin positive area appears.

Sponsors & Collaborators

  • Cancer Center of Irvine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-09-30
Completion
2020-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996993 on ClinicalTrials.gov